Q1 2022 EPS Estimates for Cryoport, Inc. Reduced by Analyst (NASDAQ:CYRX)

Cryoport, Inc. (NASDAQ:CYRXGet Rating) – Research analysts at B. Riley reduced their Q1 2022 EPS estimates for shares of Cryoport in a report issued on Thursday, May 5th. B. Riley analyst Y. Zhi now forecasts that the consumer goods maker will earn ($0.26) per share for the quarter, down from their prior estimate of ($0.21). B. Riley also issued estimates for Cryoport’s Q2 2022 earnings at ($0.19) EPS, Q3 2022 earnings at ($0.17) EPS, Q4 2022 earnings at ($0.16) EPS, FY2022 earnings at ($0.77) EPS and FY2023 earnings at $0.15 EPS.

A number of other research firms also recently issued reports on CYRX. TheStreet downgraded shares of Cryoport from a “c-” rating to a “d+” rating in a research report on Friday, January 28th. SVB Leerink increased their target price on shares of Cryoport from $75.00 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, February 25th. Roth Capital dropped their target price on shares of Cryoport from $90.00 to $67.00 in a research report on Tuesday, May 3rd. BTIG Research dropped their target price on shares of Cryoport from $95.00 to $60.00 in a research report on Friday. Finally, Needham & Company LLC reissued a “buy” rating and set a $45.00 target price on shares of Cryoport in a research report on Wednesday, April 13th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cryoport presently has an average rating of “Buy” and an average price target of $61.14.

Shares of NASDAQ:CYRX opened at $23.78 on Monday. The firm has a market capitalization of $1.18 billion, a PE ratio of -3.89 and a beta of 1.30. Cryoport has a 12 month low of $21.61 and a 12 month high of $86.30. The company has a debt-to-equity ratio of 0.64, a current ratio of 16.26 and a quick ratio of 15.88. The business has a 50-day moving average of $30.29 and a two-hundred day moving average of $47.35.

Cryoport (NASDAQ:CYRXGet Rating) last released its quarterly earnings results on Thursday, May 5th. The consumer goods maker reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.13). The company had revenue of $52.30 million for the quarter, compared to analysts’ expectations of $52.86 million. Cryoport had a negative return on equity of 13.57% and a negative net margin of 128.78%. The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.13) EPS.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Captrust Financial Advisors boosted its position in shares of Cryoport by 35.4% during the 3rd quarter. Captrust Financial Advisors now owns 624 shares of the consumer goods maker’s stock valued at $42,000 after purchasing an additional 163 shares in the last quarter. Pinebridge Investments L.P. acquired a new position in Cryoport in the 4th quarter valued at $77,000. Lindbrook Capital LLC acquired a new stake in Cryoport in the 4th quarter worth $87,000. FinTrust Capital Advisors LLC grew its position in Cryoport by 47.1% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 2,212 shares of the consumer goods maker’s stock worth $147,000 after purchasing an additional 708 shares during the last quarter. Finally, Parallel Advisors LLC acquired a new stake in shares of Cryoport during the 4th quarter valued at about $158,000.

In related news, CFO Robert Stefanovich sold 1,095 shares of the firm’s stock in a transaction on Wednesday, March 9th. The stock was sold at an average price of $31.05, for a total transaction of $33,999.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Mark W. Sawicki sold 1,410 shares of the firm’s stock in a transaction on Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total value of $43,780.50. The disclosure for this sale can be found here. Insiders sold 5,803 shares of company stock valued at $180,183 in the last ninety days. 9.70% of the stock is owned by corporate insiders.

Cryoport Company Profile (Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.

Recommended Stories

Earnings History and Estimates for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.